Berriman spent 14 years with Celltech Group and was on the company’s board when it listed on the London Stock Exchange in 1994. He has also served on the boards of Solexa, Chroma Therapeutics, Epigenomics, Alnylam, and XCounter.
Lee Babiss, Jay Stoerker, John Berriman
Roche has named Lee Babiss to the position of head of Global Pharmaceutical Research.
Babiss, who will step into the role on July 1, will be based at the company’s Basel, Switzerland, headquarters, and will be focused on disease biology areas such as virology, oncology, and others that are ongoing at various Roche facilities.
Babiss currently is vice president of preclinical research, serves on the company’s international research management team, and chairs its biomarker team.
Before joining Roche, Babiss was president of biological sciences and genetics at Glaxo Wellcome.
SensiGen, a developer of gene-based molecular diagnostics, has appointed Jay Stoerker to the position of vice president of product development. In this role, he will oversee commercial development of SensiGen’s pipeline of assays for human papillomavirus, nephrin, lupus, inflammatory bowel disease, and other indications.
Stoerker most recently led technology development at Matritech. Prior to that, he was a post-doctoral fellow at the Institute for Molecular Virology in Erlangen, Germany.
Pronota, a predictive biomarker developer, has appointed John Berriman as chairman. Berriman is currently chairman of Algeta ASA and a member of the board of directors of MicroMet, Ablynx, and Oxxon Therapeutics Holdings. Previously, he was a director of Abingworth Management.